JARISLOWSKY FRASER Ltd Lowers Position in Zoetis Inc. (NYSE:ZTS)

JARISLOWSKY FRASER Ltd reduced its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 85,714 shares of the company's stock after selling 2,161 shares during the period. JARISLOWSKY FRASER Ltd's holdings in Zoetis were worth $13,965,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Mission Wealth Management LP grew its position in Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the last quarter. VeraBank N.A. grew its position in Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after purchasing an additional 62 shares during the last quarter. HUB Investment Partners LLC grew its position in Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares during the last quarter. Procyon Advisors LLC grew its position in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after purchasing an additional 63 shares during the last quarter. Finally, Coppell Advisory Solutions LLC boosted its holdings in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after acquiring an additional 64 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ZTS has been the topic of several recent research reports. Stifel Nicolaus lowered their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Barclays increased their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Finally, Piper Sandler lifted their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $212.75.

Zoetis Price Performance

NYSE:ZTS traded down $5.64 during trading hours on Wednesday, hitting $154.77. 3,473,427 shares of the stock traded hands, compared to its average volume of 2,507,355. The company has a market cap of $68.90 billion, a price-to-earnings ratio of 28.29, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The stock has a 50 day moving average price of $156.72 and a 200 day moving average price of $165.71.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.38 earnings per share. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.